LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global pneumococcal vaccine market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
Barath Palada, lead analyst from Technavio, specializing in research on vaccines sector, says, “The global pneumococcal vaccine market is growing faster than the global vaccine market and is expected to post a CAGR of 13.69% during the period 2016-2020. In 2015, the major revenue contributor to this market was the Americas, followed by EMEA. However, there are major opportunities for the market in APAC to grow at a rapid rate and increase its revenue contribution to the global market during the forecast period.”
The global pneumococcal vaccine market is a monopoly, with Pfizer holding around 76% of the overall market share. The company's vaccine, Prevnar, reported record sales of USD 6.25 billion in 2015 and grew by nearly 40% compared to the previous year. The strong growth is mainly due to the rapid uptake of Prevnar 13. In the US alone, the revenues for the vaccine increased by 87% in FY2015, as compared with FY2014, owing to the success of commercial programs.
The top five emerging trends driving the global pneumococcal vaccine market according to Technavio healthcare and life sciences research analysts are:
- Expansion of marketing territories
- Emergence of protein-based combination pneumococcal vaccines
- AMC for pneumococcal vaccines
- Bio-terrorism
- Public–private initiatives
Expansion of marketing territories
PCVs are available in a few developing countries through GAVI alliance partners. As the cost of the vaccine is very high, only eligible countries will get access through an approval process. Till date, from the existing 73 AMC eligible countries, only 15 countries (21%) are not approved to have access to the vaccines.
“Although these regions have shown interest in introducing pneumococcal vaccine in the near future, only South Korea, India, Comoros, and Tajikistan have shown interest to apply and get access to GAVI support in 2016 based on the eligibility standards and on DTP 3rd dose coverage, which must be greater than 70% as per the application guidelines,” according to Barath.
Emergence of protein-based combination pneumococcal vaccines
There is an increasing number of new pneumococcal protein-based vaccines, which are undergoing clinical trial evaluations. These protein-based vaccines consist of serotype-independent subunit vaccines containing purified proteins and antigens that are expressed by recombinant bacteria. These vaccines will avoid the problems of serotype replacement by directly targeting proteins that are highly preserved among many pneumococcal serotypes.
Another conserved virulence factor, pneumolysin, has shown to help protect against the infection when given in combination with other proteins. Derivatives of pneumolysin toxoid are currently being evaluated in clinical trials. Thus, the emergence of protein-based pneumococcal vaccine in combination with other vaccines will have a positive impact on the market.
AMC for pneumococcal vaccines
The pneumococcal AMC encourages the production and development of affordable vaccines tailored to the needs of developing countries. In June 2009, the governments of the UK, Italy, the Russian Federation, Canada, Norway, and the Bill & Melinda Gates Foundation collectively guaranteed a total of USD 1.5 billion to fund a pilot AMC against pneumococcal diseases. The aim was to decrease mortality and morbidity due to the disease and to prevent a projected seven million deaths by 2030.
The objectives of the pneumococcal AMC is to bring about effective pneumococcal vaccine for developing countries by ensuring the original purchase price for a limited quantity of novel vaccines that signifies value for money and incentivizes manufacturers to invest in scaling up production capacity to meet the vaccine demand in developing countries.
Bio-terrorism
Bioterrorism refers to an intentional release of bacteria, viruses, fungi, or toxins from living organisms to cause illness or death among people, animals, or plants. This is a result of globalization; wherein new contagious diseases have evolved. This has created space for the development of new vaccines to combat bioterrorism. Developed nations are taking measures to check the potential threat of bioterrorism. Bioterror-induced outbreak of diseases may lead to mass vaccination programs, creating large demand for vaccines, including pneumococcal vaccine.
Public–private initiatives
“There has been a significant increase in public–private partnerships in developing countries. Immunization programs by various governments are effectively backed by global organizations such as the WHO, UNICEF, and GAVI. More research and technical expertise is being used in public–private partnerships for better developments. All these initiatives will help the global pneumococcal vaccine market grow and will further contribute to achieve the immunization-related global goals,” asserts Barath.
Browse Related Reports:
- Global Meningococcal Vaccines Market 2016-2020
- Global H1N1 Vaccines Market 2016-2020
- Global Human Vaccine Market 2016-2020
Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
